Table 4.
Comparison of clinical outcomes between midodrine/octreotide and norepinephrinetreated patients
| Outcome | Midodrine / Octreotide | Norepinephrine | ||
|---|---|---|---|---|
| Presumed HRS (n = 73) |
Definite HRS (n = 27) |
Presumed HRS (n = 14) |
Definite HRS (n = 6) |
|
| ↑ MAP > 15 mmHga | 19 (26.0) | 7 (25.9) | 9 (64.2)c | 6 (100.0)d |
| Transitioned to norepinephrine | 11 (15.1) | 4 (14.8) | - | - |
| > 50% ↓ in sCra | 11 (15.1) | 4 (14.8) | 6 (42.9)e | 3 (50.0) |
| > 25% ↓ in sCr by 48 h. | 7 (9.6) | 3 (11.1) | 4 (28.6) | 2 (33.3) |
| >100% ↑ in urine volume by 48 h.b | 21/63 (33.3) | 5/20 (25) | 5/12 (41.7) | 3/5 (60.0) |
| Need for dialysis | 14 (19.1) | 5 (18.5) | 2 (14.3) | 1 (16.7) |
| Discharged home | 23 (31.5) | 11 (40.7) | 3 (21.4) | 2 (33.3) |
| Discharged as ESRD | 4 (5.5) | 2 (7.4) | 1 (7.1) | 1 (16.7) |
| Underwent OLT | 7 (9.6) | 1 (3.7) | 2 (14.3) | 1 (16.7) |
| Death | 14 (19.2) | 5 (18.5) | 5 (35.7) | 1 (16.7) |
| Palliative | 16 (21.9) | 4 (14.8) | 4 (28.6) | 2 (33.3) |
Data are presented as number of cases (%).
a
At any point during therapy.
b
Accurate daily urine volume was not available in all patients
c
P value = 0.01 vs. midodrine/octreotide (presumed HRS);
d
P value < 0.005 vs. midodrine/octreotide (definite HRS);
e
P value < 0.05 vs. midodrine/octreotide (presumed HRS).
Abbreviations: HRS, hepatorenal syndrome; MAP, mean arterial pressure; sCr, serum creatinine; ESRD, end-stage renal disease; OLT, orthotopic liver transplantation.